A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
61 enrolled 29 charts
APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma
Phase 1/2 Terminated
21 enrolled
CLAUDIO-01
Phase 1/2 Terminated
31 enrolled 34 charts
MK-2140-002
Phase 2 Terminated
102 enrolled 36 charts
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Phase 1/2 Terminated
8 enrolled 12 charts
Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma
Phase 1/2 Terminated
1 enrolled 3 charts
PAVO
Phase 2 Terminated
22 enrolled 17 charts
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Phase 1 Terminated
10 enrolled
Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers
Phase 1 Terminated
58 enrolled
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Phase 2 Terminated
23 enrolled 15 charts
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
Phase 1 Terminated
75 enrolled
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
Phase 1 Terminated
44 enrolled
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Terminated
19 enrolled
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
Phase 1 Terminated
33 enrolled
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
Phase 1 Terminated
19 enrolled 6 charts
QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer
Phase 1/2 Terminated
81 enrolled 13 charts
L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
Phase 1/2 Terminated
28 enrolled
Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
Phase 1 Terminated
63 enrolled
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Phase 2 Terminated
54 enrolled 11 charts
Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies
Phase 1 Terminated
118 enrolled
V941-001
Phase 1 Terminated
70 enrolled 18 charts
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis
Phase 1 Terminated
40 enrolled
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
Phase 1 Terminated
7 enrolled
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
Phase 1/2 Terminated
6 enrolled 15 charts
Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
Phase 1 Terminated
12 enrolled
Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas
Phase 2 Terminated
10 enrolled 10 charts
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer
Phase 2/3 Terminated
130 enrolled 13 charts
CAR
Phase 1 Terminated
9 enrolled
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Phase 2 Terminated
315 enrolled 73 charts
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
Phase 1/2 Terminated
13 enrolled 24 charts
Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors
Phase 1 Terminated
52 enrolled
QUILT-3.080: NANT Pancreatic Cancer Vaccine
Phase 1/2 Terminated
3 enrolled 13 charts
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
Phase 1/2 Terminated
89 enrolled 20 charts
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Phase 1/2 Terminated
7 enrolled
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
Phase 1/2 Terminated
3 enrolled 6 charts
Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer
Phase 2/3 Terminated
39 enrolled
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
49 enrolled 33 charts
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
Phase 1 Terminated
78 enrolled 39 charts
QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
Phase 1/2 Terminated
3 enrolled 9 charts
QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
Phase 1/2 Terminated
4 enrolled 9 charts
MYCure
Phase 1/2 Terminated
22 enrolled 9 charts
A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
Phase 3 Terminated
5 enrolled
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Phase 1 Terminated
127 enrolled
A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma
Phase 1 Terminated
29 enrolled
OH2 Oncolytic Viral Therapy in Pancreatic Cancer
Phase 1/2 Terminated
5 enrolled
Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
Phase 2 Terminated
2 enrolled 10 charts
LODESTAR
Phase 2 Terminated
83 enrolled 16 charts
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Phase 1 Terminated
5 enrolled
GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
Phase 1/2 Terminated
48 enrolled 29 charts